Compare 10X Genomics Inc (TXG) vs Williams Companies Inc (WMB) Price & Performance

TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.

Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.

WMB trades at $75.83, up 2.27% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q2 2026 earnings but maintains robust profitability with a 25.18% net income margin. Recent developments include the $5.5 billion acquisition of Momentum Midstream, enhancing its natural gas infrastructure, while a court ruling vacated a key permit for the NESE pipeline project.

The stock offers growth exposure to natural gas demand driven by LNG exports and AI infrastructure, with a consensus price target of $88.14 implying 16% upside. Risks include regulatory hurdles for pipeline projects and high debt levels, but strong cash flow supports dividends and expansion.